Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models

Por Anderson, Rachel I., Becker, Howard C., Adams, Benjamin L., Jesudason, Cynthia D., Rorick-Kehn, Linda M.
Publicado em 2014

Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience to the Development of Drug Addiction

Por Kallupi, Marsida, Scuppa, Giulia, de Guglielmo, Giordano, Calò, Girolamo, Weiss, Friedbert, Statnick, Michael A, Rorick-Kehn, Linda M, Ciccocioppo, Roberto
Publicado no Neuropsychopharmacology (2017)

The Biology of Nociceptin/Orphanin FQ (N/OFQ) Related to Obesity, Stress, Anxiety, Mood, and Drug Dependence()

Por Witkin, Jeffrey M., Statnick, Michael A., Rorick-Kehn, Linda M., Pintar, John E., Ansonoff, Michael, Chen, Yanyun, Tucker, R. Craig, Ciccocioppo, Roberto
Publicado no Pharmacol Ther (2013)

The Muscarinic Acetylcholine Receptor Agonist BuTAC Mediates Antipsychotic-Like Effects via the M4 Subtype

Por Watt, Marla L, Rorick-Kehn, Linda, Shaw, David B, Knitowski, Karen M, Quets, Anne T, Chesterfield, Amy K, McKinzie, David L, Felder, Christian C
Publicado em 2013

LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy

Por Fitch, Thomas E., Benvenga, Mark J., Jesudason, Cynthia D., Zink, Charity, Vandergriff, Amy B., Menezes, Michelle M., Schober, Douglas A., Rorick-Kehn, Linda M.
Publicado em 2014

Duration of Action of a Broad Range of Selective κ-Opioid Receptor Antagonists Is Positively Correlated with c-Jun N-Terminal Kinase-1 Activation

Por Melief, Erica J., Miyatake, Mayumi, Carroll, F. Ivy, Béguin, Cécile, Carlezon, William A., Cohen, Bruce M., Grimwood, Sarah, Mitch, Charles H., Rorick-Kehn, Linda, Chavkin, Charles
Publicado em 2011

A novel, orally-bioavailable nociceptin receptor antagonist, LY2940094, reduces ethanol self-administration and ethanol-seeking in animal models

Por Rorick-Kehn, Linda M., Ciccocioppo, Roberto, Wong, Conrad J., Witkin, Jeffrey M., Martínez-Grau, Maria A., Stopponi, Serena, Adams, Benjamin L., Katner, Jason S., Perry, Kenneth W., Toledo, Miguel A., Diaz, Nuria, Lafuente, Celia, Jiménez, Alma, Benito, Ana, Pedregal, Concepcion, Weiss, Friedbert, Statnick, Michael A.
Publicado no Alcohol Clin Exp Res (2016)

Determining Pharmacological Selectivity of the Kappa Opioid Receptor Antagonist LY2456302 Using Pupillometry as a Translational Biomarker in Rat and Human

Por Rorick-Kehn, Linda M., Witcher, Jennifer W., Lowe, Stephen L., Gonzales, Celedon R., Weller, Mary Ann, Bell, Robert L., Hart, John C., Need, Anne B., McKinzie, Jamie H., Statnick, Michael A., Suico, Jeffrey G., McKinzie, David L., Tauscher-Wisniewski, Sitra, Mitch, Charles H., Stoltz, Randall R., Wong, Conrad J.
Publicado no Int J Neuropsychopharmacol (2015)

Preclinical findings predicting efficacy and side‐effect profile of LY2940094, an antagonist of nociceptin receptors

Por Witkin, Jeffrey M., Rorick‐Kehn, Linda M., Benvenga, Mark J., Adams, Benjamin L., Gleason, Scott D., Knitowski, Karen M., Li, Xia, Chaney, Steven, Falcone, Julie F., Smith, Janice W., Foss, Julie, Lloyd, Kirsti, Catlow, John T., McKinzie, David L., Svensson, Kjell A., Barth, Vanessa N., Toledo, Miguel A., Diaz, Nuria, Lafuente, Celia, Jiménez, Alma, Benito, Alfonso, Pedregal, Conception, Martínez‐Grau, Maria A., Post, Anke, Ansonoff, Michael A., Pintar, John E., Statnick, Michael A.
Publicado no Pharmacol Res Perspect (2016)